HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Commissioner Mary Sheila Gall's confirmation to chair consumer product safety agency delayed due to postponement of June 6 Senate Commerce Committee hearing. Sen. James Jeffords' (I-Vt.) defection from GOP continues to disrupt committee actions as panels are realigned. Trade groups, who view Gall as more industry-friendly, have expressed concern about delay (1"The Tan Sheet" May 14, In Brief). Gall, a holdover from George H. W. Bush's administration, is seen as less apt to aggressively publicize unsafe products. She recently voted to proceed with rulemaking on mandatory Rx-to-OTC switch child-resistant packaging regs, although action on rule is expected to move slowly, according to CHPA

You may also be interested in...


Commissioner Mary Gall, Bush Administration nominee to assume chairman's post, is not expected to have "same ideological bent vis-a-vis child-resistant packaging as [current chairman] Ann Brown," Healthcare Compliance Packaging Council Exec Director Peter Mayberry suggests at HCPC's patient compliance symposium in Philadelphia May 8. CPSC's three commissioners serve staggered, seven-year terms; chairman serves at President's discretion. HCPC has criticized proposed rule requiring CRP on all new oral Rx-to-OTC switches and Gall has voiced concerns about placing added burdens on manufacturers. CPSC staff briefing package on proposed rule and comments is expected to be distributed to commissioners in late May/early June. Mayberry says

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts